BFC Planning, Inc.’s BioLineRX BLRX Stock Holding History

BFC Planning, Inc.’s Portfolio BLRX Stock Details BLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87	Buy	+28	New	+$81	﹤0.01%	3359

Other funds holding BLRX

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Banque Cantonale Vaudoise Lausanne, Switzerland $722M AUM 30.45% 1-Year Est. Return

Nemes Rush Group Novi, Michigan $1.21B AUM 33.22% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

BFC Planning, Inc.'s BLRX Position: Q2 2026 in Review

BFC Planning, Inc. opened a new position in BioLineRX (BLRX) in Q2 2026: 28 shares worth $87. The stake represents ﹤0.01% of the portfolio and ranks #3359 among its holdings.

15 funds tracked by Wall St. Rank hold BLRX as of Q2 2026.

BFC Planning, Inc. held 28 shares of BioLineRX worth $87 as of Q2 2026.
BioLineRX was a new BFC Planning, Inc. position in Q2 2026.
BioLineRX made up ﹤0.01% of BFC Planning, Inc.'s portfolio in Q2 2026, its #3359 holding.
15 funds tracked by Wall St. Rank held BioLineRX as of Q2 2026.

Based on BFC Planning, Inc.'s 13F filing for Q2 2026, filed 29 Oct 2026.